News

Filter

Current filters:

NicOx

1 to 9 of 96511 results

Eylea beats Avastin and Lucentis for visual acuity in DME patients

Eylea beats Avastin and Lucentis for visual acuity in DME patients

19-10-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer saw their shares leap 8.5% to…

AvastinBayerBiotechnologyEyleaGenentechLucentisNovartisOphthalmicsRegeneron PharmaceuticalsResearchRoche

Amgen sues Sanofi and Regeneron over alleged patent infringement

19-10-2014

USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabLegalPatentsRegeneron PharmaceuticalsSanofiUSA

Horizon Pharma buys US rights to Nuvo’s Pennsaid for $45 million

19-10-2014

Canadian specialty drugmaker Nuvo Research says it has completed the sale of its osteoarthritis pain…

Anti-Arthritics/RheumaticsHorizon PharmaLicensingMallinckrodtNuvo ResearchPennsaidPharmaceuticalUSA

Indian government takes action on country’s growing mental health problems

18-10-2014

Stigma, ignorance and a severe lack of doctors in India have long marred mental health care projects…

Human InterestIndiaNeurologicalPharmaceutical

GSK Ebola vaccine “too late” for current Ebola outbreak; more on Ebola

17-10-2014

UK pharma giant GlaxoSmithKline says any Ebola vaccine it produces will come too late for the current…

Anti-viralsAVI-6002GlaxoSmithKlinePharmaceuticalProductionResearchSarepta Therapeutics

Profectus BioSciences gets US government funding for Ebola vaccine development

17-10-2014

Under a one-year contract with US biotech firm Profectus BioSciences, the US Department of Health and…

Anti-viralsBiotechnologyFinancialProfectus BioSciencesResearchUSA

Pharmacyclics’ Imbruvica gains EU approval for two blood cancers

17-10-2014

US drugmaker Pharmacyclics has received marketing approval from the European Commission for Imbruvica…

EuropeImbruvicaJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulation

1 to 9 of 96511 results

Parexel

Parexel

Back to top